NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 72 resultados LastUpdate Última actualización 19/10/2021 [15:30:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   por página


EXTRACELLULAR VESICLE SECRETION INHIBITOR FOR INHIBITING EXTRACELLULAR VESICLE SECRETION, AND USE OF THE SAME

NºPublicación: WO2021206105A1 14/10/2021

Solicitante:

THEORIA SCIENCE INC [JP]

Resumen de: WO2021206105A1

Provided are a novel secretion inhibitor and a secretion inhibiting method relating to the secretion of an extracellular vesicle from a cell. This extracellular vesicle secretion inhibitor is characterized by containing an agent that blocks the serine synthesis pathway. Said cell is, for instance, a cancer cell such as a colon cancer cell, a lung cancer cell, a melanoma cell, a breast cancer cell, a pancreatic cancer cell, or a multiple myeloma cell.

traducir

USE OF EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF LIVER CANCER, MELANOMA, LYMPHOMA AND LEUKEMIA

NºPublicación: WO2021205367A1 14/10/2021

Solicitante:

ASKAT INC [JP]

Resumen de: WO2021205367A1

This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of liver cancer, melanoma, lymphoma and leukemia in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist and may include one or more other active agents and/or therapies for liver cancer therapy, such as an anti-PD-1 antibody.

traducir

BINDERS AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN

NºPublicación: WO2021207709A1 14/10/2021

Solicitante:

SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST [US]
PROVINCIAL HEALTH SERVICES AUTHORITY [CA]
UNIV OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US]

Resumen de: WO2021207709A1

Some embodiments provided herein also include methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to an IL1RAP polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to an IL1RAP polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided. Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CARs) which specifically bind to interleukin-1 receptor accessory protein (IL1RAP). Some embodiments include nucleic acids encoding such CARs, and cells containing such CARs. Some embodiments include the use of such CARs in safe and effective therapies for a cancer, such as an IL1RAP-expressing cancer, such as a Ewing's sarcoma and acute myeloid leukemia (AML).

traducir

Aniline WDR5 protein-protein interaction inhibitor, preparation method therefor and use thereof

NºPublicación: AU2019431157A1 14/10/2021

Solicitante:

UNIV CHINA PHARMA

WO_2020172932_A1

Resumen de: AU2019431157A1

Disclosed is a WDR5 protein-protein interaction inhibitor, containing a compound with a structure as shown in general formula (I). Experiments show that the inhibitor acts on the WDR5 protein and interacting proteins thereof, including, but not limited to, MLL, selectively inhibits the proliferation of leukemia cells, and inhibits, at a cellular level, the methylation of H3K4 and the expression of a downstream Hox/Meis-1 gene. Also disclosed are a method for preparing the inhibitor and the use thereof in the preparation of a drug for treating acute leukemia and other related diseases.

traducir

Methods and Pharmaceutical Compositions for Treating Lymphoid Malignancy

NºPublicación: US2021315901A1 14/10/2021

Solicitante:

UNIV COLUMBIA [US]

US_2019209570_A1

Resumen de: US2021315901A1

The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.

traducir

CD47 BLOCKADE WITH PARP INHIBITION FOR DISEASE TREATMENT

NºPublicación: US2021315864A1 14/10/2021

Solicitante:

TRILLIUM THERAPEUTICS INC [CA]

CN_112739384_A

Resumen de: US2021315864A1

CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRPαFc and the PARP inhibitor niraparib. The anti-cancer effect of niraparib is enhanced in the presence of SIRPαFc. Specific combinations include SIRPαFc forms that comprise an Fc that is either IgG1 or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.

traducir

COMBINATORY TREATMENT FOR LYMPHOMA

NºPublicación: WO2021205025A1 14/10/2021

Solicitante:

UNIV PARIS [FR]
INST NAT SANTE RECH MED [FR]
HOPITAUX PARIS ASSIST PUBLIQUE [FR]

EP_3892267_A1

Resumen de: WO2021205025A1

The invention relates to the field of medicine and more particularly to novel combinations and combinatory treatments useful for treating lymphoma. More particularly, the invention thus relates to a combination comprising at least one inhibitor of glutamine metabolism or a pharmaceutically acceptable salt, prodrug, derivative, or sustained release formulation thereof and at least one inhibitor of mitochondrial electron transport chain or a pharmaceutically acceptable salt, prodrug, derivative, or sustained release formulation thereof, for its use in the treatment or the prevention of a lymphoma in a subject in need thereof.

traducir

METHODS AND USES RELATED TO CELL THERAPY ENGINEERED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING B-CELL MATURATION ANTIGEN

NºPublicación: WO2021207689A2 14/10/2021

Solicitante:

JUNO THERAPEUTICS INC [US]

Resumen de: WO2021207689A2

Provided are methods and uses related to adoptive cell therapy involving the administration of doses of cells, such as T cells, for treating disease and conditions, including certain plasma cell malignancies. The cells express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM).

traducir

USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS

NºPublicación: EP3892264A2 13/10/2021

Solicitante:

ONCOIMMUNE INC [US]

US_2021161991_A1

Resumen de: EP3892264A2

The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.

traducir

COMBINATORY TREATMENT FOR LYMPHOMA

NºPublicación: EP3892267A1 13/10/2021

Solicitante:

UNIV PARIS [FR]
INST NAT SANTE RECH MED [FR]
HOPITAUX PARIS ASSIST PUBLIQUE [FR]

WO_2021205025_A1

Resumen de: EP3892267A1

The invention relates to the field of medicine and more particularly to novel combinations and combinatory treatments useful for treating lymphoma. More particularly, the invention thus relates to a combination comprising at least one inhibitor of glutamine metabolism or a pharmaceutically acceptable salt, prodrug, derivative, or sustained release formulation thereof and at least one inhibitor of mitochondrial electron transport chain or a pharmaceutically acceptable salt, prodrug, derivative, or sustained release formulation thereof, for its use in the treatment or the prevention of a lymphoma in a subject in need thereof.

traducir

COMPOSITIONS CONTAINING IBRUTINIB

NºPublicación: EP3892302A1 13/10/2021

Solicitante:

JANSSEN PHARMACEUTICA NV [BE]

US_2020171036_A1

Resumen de: EP3892302A1

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

traducir

ENGINEERED IMMUNE CELLS FOR ADOPTIVE CELL THERAPY

NºPublicación: WO2021202581A1 07/10/2021

Solicitante:

WUGEN INC [US]

Resumen de: WO2021202581A1

Disclosed herein are engineered immune cells, which can be derived from allogeneic or autologous donors, and can be selected from B cells, T cells (CD4+ helper T cells, CD8+ T cells, natural killer T cells, γδ T cells, regulatory T cells, mucosal-associated invariant T cells, and memory T cells), monocytes /macrophages, antigen presenting cells (APCs), such as dendritic cells, and and stem cells, such as induced pluripotent stem cells (iPS cells), engineered to express and secrete a soluble NKG2D (natural-killer receptor group 2, member D) ligand, such as orthopoxvirus major histocompatibility complex (MHC) class I-like protein (OMCP). The engineered immune cells may further comprise one or more chimeric antigen receptors (CARs) targeting one or more antigens, wherein the immune cell is deficient in one or more antigens to which the one or more CARs specifically binds. Methods of immunotherapy for the treatment of diseases including cancers, such as hematological cancers, leukemias, lymphomas, and multiple myeloma, and infections, autoimmune disorders, radiation sickness, and methods to prevent or treat host-versus-graft disease (HvGD) or transplantation rejection in a human recipient undergoing transplant, are also disclosed herein.

traducir

HUMAN ANTI-CD33 ANTIBODIES AND USES THEREOF

NºPublicación: WO2021202770A2 07/10/2021

Solicitante:

HUTCHINSON FRED CANCER RES [US]

Resumen de: WO2021202770A2

A suite of novel human anti-CD33 antibodies is described. The provided antibodies are pan-binders, binding the C2-set Ig-like domain in the presence or absence of the V-set Ig-like domain of CD33 or are V-set binders, binding the V-set Ig-like domain of CD33. The antibodies provide novel therapeutic and diagnostic tools against CD33-related disorders, such as acute myeloid leukemia (AML).

traducir

BIOMARKER PANELS FOR STRATIFICATION OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN CANCER

NºPublicación: WO2021202755A2 07/10/2021

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

Resumen de: WO2021202755A2

The present invention describes methods of detecting biomarkers in tumor tissue, as well as methods of improving responsiveness to or providing survival prognosis for a subject having received or in need of, an immune checkpoint inhibitor in the treatment of cancers such as bladder cancer, lung cancer, leukemia. Discoidin domain receptor (DDR)-driven gene signatures have been identified and validated to stratify patient response to anti-PD-L1 immune checkpoint therapy.

traducir

VACCINE COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS

NºPublicación: WO2021198769A1 07/10/2021

Solicitante:

VARIATION BIOTECHNOLOGIES INC [CA]

Resumen de: WO2021198769A1

The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.

traducir

Substituted bicyclic and tetracyclic quinones and related methods of use

NºPublicación: AU2020232008A1 07/10/2021

Solicitante:

UNIV MICHIGAN REGENTS

WO_2020181207_A1

Resumen de: AU2020232008A1

This invention is in the field of medicinal chemistry. In particular, the invention relates to small molecule compounds having bicyclic and tetracyclic quinone scaffolds which have antiproliferative activities through, for example, induction of reactive oxygen species. The invention further processes for preparing, and methods for using these compounds to treat cancer (e.g., pancreatic cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer).

traducir

Car T-cells for the treatment of CD1a-positive cancer

NºPublicación: AU2020222239A1 07/10/2021

Solicitante:

FUNDACION INSTITUO DE INVESTIG CONTRA LA LEUCEMIA JOSEP CARRERAS IJC
INST CATALANA DE RECERCA I ESTUDIS AVANCATS ICREA
FUNDACIO INST DINVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL IGTP

WO_2020165350_A1

Resumen de: AU2020222239A1

Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor T-cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CARTs fratricide. CD la is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD la is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD la during ontogeny, confining the risk of on-target/off-tumor toxicity. The present invention provides CARs comprising a CD la-targeting moiety which may be transduced or transformed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.

traducir

Crystalline forms of an RSK inhibitor

NºPublicación: AU2020222056A1 07/10/2021

Solicitante:

PHOENIX MOLECULAR DESIGNS

WO_2020165646_A1

Resumen de: AU2020222056A1

Described herein are crystalline forms of (R)-N-(1-(4-aminobenzyl)-1H-pyrazol-4-yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido[3',2':4,5]- pyrrolo [ 1,2-a]pyrazine-2-carboxamide hydrochloride and solvates thereof; pharmaceutical compositions and use thereof in treating cancer such as breast cancer, prostate cancer, lung cancer, brain cancer, skin cancer, bone cancer, ovarian cancer, multiple myeloma and leukemia. Compound (I)

traducir

METHOD FOR DIAGNOSIS, PROGNOSIS AND DETERMINATION OF TREATMENT FOR CUTANEOUS T-CELL LYMPHOMA

NºPublicación: US2021311062A1 07/10/2021

Solicitante:

UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION [US]

US_2020033348_A1

Resumen de: US2021311062A1

The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.

traducir

HYDROXYAPATITE POWDER AND PROCESS FOR PRODUCING SAME, COMPOSITION BASED ON THIS POWDER AND PROCESS FOR PREPARING SAME AND KIT COMPRISING THIS POWDER

NºPublicación: US2021308259A1 07/10/2021

Solicitante:

URODELIA [FR]

ES_2820538_T3

Resumen de: US2021308259A1

The present invention relates to a hydroxyapatite and/or tricalcium phosphate powder characterized in that it has undergone at least one sintering step at a temperature between 400° C. and 600° C. The invention also relates to a process for preparing such a powder, and to a composition comprising such a powder for use as an anti-tumour auto-vaccine and particularly in the treatment of the following pathological conditions: osteosarcoma, B or T lymphoma, mammary tumour, melanoma, haemangiosarcoma, mastocytoma, fibrosarcoma, brain tumours and schwannoma in a subject. The present invention also covers a drug combination comprising the composition of the invention and at least one second therapeutic agent, preferably an anti-tumour agent and/or a radiotherapeutic agent.

traducir

COMBINATION OF CANNABINOIDS IN THE TREATMENT OF LEUKAEMIA

NºPublicación: US2021308072A1 07/10/2021

Solicitante:

GW RES LTD [GB]

US_2020022925_A1

Resumen de: US2021308072A1

The present invention relates to the use of a combination of two different cannabinoids in the treatment of leukaemia. The combination of CBD with THC appears to be particularly effective in reducing cell number in this disease. Preferably the cannabinoids are used in the form of an extract of cannabis such that many of the naturally occurring compounds are co-extracted with the THC or CBD. Alternatively, the cannabinoids are present in the form of a highly purified extract of cannabis, wherein the CBD or THC are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterized. Alternatively, the CBD and THC may be synthetically produced. A specific ratio of CBD and THC such as 10:1 to 1:10 (CBD:THC) or more preferably between 2:1 to 1:2 (CBD:THC) may be used.

traducir

CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES

NºPublicación: WO2021197452A1 07/10/2021

Solicitante:

SHANGHAI HANSOH BIOMEDICAL CO LTD [CN]
JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD [CN]

Resumen de: WO2021197452A1

The present invention relates to a crystal form of the free alkali of nitrogen-containing aromatic derivatives. In particular, the present invention relates to a crystal form of the compound represented by the general formula (I), its preparation method and a pharmaceutical composition containing a therapeutically effective amount of the crystal form, and the use thereof as a protein tyrosine phosphatase-2C (SHP2) inhibitor in the treatment of diseases or conditions such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colorectal cancer.

traducir

ANTI-CD33 ANTIBODIES AND USES THEREOF

NºPublicación: WO2021202726A2 07/10/2021

Solicitante:

HUTCHINSON FRED CANCER RES [US]

Resumen de: WO2021202726A2

A suite of novel anti-CD33 antibodies is described. The provided antibodies are pan-binders, binding the C2-set Ig-like domain in the presence or absence of the V-set Ig-like domain of CD33; are C2-set specific binders, binding the C2-set Ig-like domain only in the absence of the V-set Ig-like domain of CD33; or are V-set binders, binding the V-set Ig-like domain of CD33. The antibodies provide novel therapeutic and diagnostic tools against CD33-related disorders, such as acute myeloid leukemia (AML).

traducir

CXCR5 ANTAGONISTS AND METHODS OF TREATING DISEASES OR DISORDERS USING SAME

NºPublicación: WO2021202553A1 07/10/2021

Solicitante:

UNIV YALE [US]

Resumen de: WO2021202553A1

The disclosure provides compounds, and compositions comprising such compounds, that can be used to treat CXCR5-expressing cancers, especially angioimmunoblastic T cell lymphoma (AICL) and/or cutaneous T cell lymphoma (CTCL).

traducir

BENZOTHIAZOLE DERIVATIVE COMPOUND

Nº publicación: WO2021201576A1 07/10/2021

Solicitante:

INNOCURE THERAPEUTICS INC [KR]

Resumen de: WO2021201576A1

The present invention relates to an anticancer agent for treating leukemia or solid cancers, comprising a novel benzothiazole derivative compound or a pharmaceutically acceptable salt thereof, wherein the benzothiazole derivative compound inhibits Abl kinase, and thus can be effectively used for the treatment of leukemia, which exhibits resistance to conventional anticancer agents.

traducir

Página1 de 3 nextPage por página

punteroimgVolver